Skip to content

Arcutis Biotherapeutics, Inc. ARQT Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Incyte logo
IncyteINCY
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s convertible preferred stock outstanding shares?
Arcutis Biotherapeutics, Inc. (ARQT) reported convertible preferred stock outstanding shares of 0 in Q1 2026.